Journal
Empower Pharmacy and Your GLP-1: The September 2026 FDA Warning Letter, and How to Check a Pharmacy
Released: Last reviewed:
The short answer
Empower Pharmacy is a Houston, Texas–based compounding operation and one of the most recognized names in US compounding. Its public materials describe operations spanning both compounding lanes — traditional patient-specific 503A dispensing and FDA-registered 503B outsourcing. The most important current fact is the FDA warning letter 738238, dated September 18, 2026, which says Empower's compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites insanitary conditions. If a telehealth program tells you Empower will fill your prescription, read that letter and ask the program, in writing, how the product you would receive relates to what the letter describes. This page is not an endorsement or an inspection report; it's the same fifteen-minute vetting process applied, because scale is a fact about a pharmacy, not a verdict on it.
Why the 503A/503B distinction is the Empower question
A 503A pharmacy compounds per individual prescription under state-board oversight; a 503B outsourcing facility registers with the FDA, compounds in bulk under federal GMP, and gets FDA inspections as a matter of routine. Post-shortage, GLP-1 copies exited the 503B bulk lane (production wound down in 2025; on April 30, 2026 the FDA proposed not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list, 91 FR 23431, extended the comment period to July 30, 2026, 91 FR 38719, and had made no final decision as of October 15, 2026), so the GLP-1 prescription a telehealth program routes to Empower today travels the patient-specific 503A lane — the state-regulated one, where federal pre-market review doesn't apply. The practical upshot for a buyer: an organization's 503B experience with GMP-grade systems is a reasonable thing to weigh, and it changes nothing about which checks you run, because your specific vial's lane is 503A either way. Verify the current registrations yourself: state board records for the 503A license, and the FDA's published list of registered outsourcing facilities for any 503B entity — both public, both current, both a two-minute search.
The five checks, Empower edition
One: the Texas State Board of Pharmacy lookup for the home license, then your state board's lookup for the non-resident license that lets it ship to you — active, unencumbered, or the conversation ends there. Two: the FDA's human-drug-compounding pages — inspection outcomes, Form 483s, warning letters, recalls — searched by name; for Empower, that search now returns warning letter 738238 (September 18, 2026), and the letter's findings are the record to read, not the reputation. Three: the lane confirmation above. Four: accreditation — ask whether the dispensing entity holds PCAB/ACHC accreditation and expect a verifiable certificate number, not a logo. Five: the certificate of analysis — third-party identity, potency, and sterility testing for your lot, on request, in writing. A pharmacy of Empower's scale can answer all five in one email; the answers, not the size, are the point.
What scale does and doesn't tell you
Big compounders bring real advantages — invested quality systems, tested supply chains, the staffing to answer a COA request same-day — and one structural caution: a large pharmacy serves many telehealth brands at once, so the program you buy from is a customer of the pharmacy, not its overseer, and program-level claims ("our pharmacy tests everything") are only as good as the pharmacy-level documents behind them. Which returns every road to the same place: the program should name its pharmacy, the pharmacy's records should check out (fifteen minutes, above), and the COA should exist for your lot. Being named is only the first test; for Empower, the FDA record now includes a September 2026 warning letter, and the remaining checks are yours to run with the lookups on this page.
Questions people ask
Is Empower Pharmacy legitimate for compounded GLP-1s?
It is a large, Houston-based compounding operation. On September 18, 2026 the FDA sent it warning letter 738238 (posted September 22, 2026), saying its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and citing insanitary conditions. Read the letter, check its Texas and your-state licenses on board lookups, and ask for a certificate of analysis for your lot. This site has not independently inspected any pharmacy.
Is Empower a 503A or 503B pharmacy?
Its public materials describe operations in both lanes — patient-specific 503A dispensing and FDA-registered 503B outsourcing. Post-shortage, GLP-1 prescriptions travel the 503A patient-specific lane regardless (503B bulk GLP-1 compounding wound down in 2025, and the FDA's April 30, 2026 proposal not to place tirzepatide or semaglutide on the 503B bulks list had no final decision as of October 15, 2026), so your vial is a 503A product either way; verify current registrations on the Texas board lookup and the FDA's registered outsourcing facilities list.
Which GLP-1 telehealth programs use Empower?
We don't publish a list of which programs use Empower, and programs can change pharmacies. Ask any program, in writing, which pharmacy will fill your prescription in your state. NexLife's plan pages (read October 15, 2026) name three other pharmacies — Absolute Pharmacy, Premium Compounding and Boudreaux's New Drug Store — not Empower.
Does a bigger pharmacy mean a safer GLP-1?
Scale brings invested quality systems and responsive documentation, but it isn't a verdict — the checks are identical at any size: state licenses (home and yours), FDA inspection/recall records, accreditation with a verifiable certificate, and a lot-specific certificate of analysis. Read records, not reputations.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.